Cannabidiol protects dopaminergic neuronal cells from cadmium by Branca, J. J. V. et al.
International  Journal  of
Environmental Research
and Public Health
Article
Cannabidiol Protects Dopaminergic Neuronal Cells
from Cadmium
Jacopo Junio Valerio Branca 1,* , Gabriele Morucci 1,*, Matteo Becatti 2 , Donatello Carrino 1,
Carla Ghelardini 3, Massimo Gulisano 1, Lorenzo Di Cesare Mannelli 3 and Alessandra Pacini 1
1 Department of Experimental and Clinical Medicine, Histology and Anatomy Section, University of Firenze,
50134 Firenze, Italy; donatello.carrino@unifi.it (D.C.); massimo.gulisano@unifi.it (M.G.);
alessandra.pacini@unifi.it (A.P.)
2 Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Firenze,
50134 Firenze, Italy; matteo.becatti@unifi.it
3 Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA),
Pharmacology and Toxicology Section, University of Firenze, 50139 Firenze, Italy;
carla.ghelardini@unifi.it (C.G.); lorenzo.mannelli@unifi.it (L.D.C.M.)
* Correspondence: jacopojuniovalerio.branca@unifi.it (J.J.V.B.); gabriele.morucci@unifi.it (G.M.);
Tel.: +39-055-2758067 (J.J.V.B.)
Received: 21 October 2019; Accepted: 5 November 2019; Published: 12 November 2019


Abstract: The protective effect of cannabidiol (CBD), the non-psychoactive component of Cannabis sativa,
against neuronal toxicity induced by cadmium chloride (CdCl2 10 µM) was investigated in a retinoic
acid (RA)-differentiated SH-SY5Y neuroblastoma cell line. CBD (1 µM) was applied 24 h before and
removed during cadmium (Cd) treatment. In differentiated neuronal cells, CBD significantly reduced
the Cd-dependent decrease of cell viability, and the rapid reactive oxygen species (ROS) increase. CBD
significantly prevented the endoplasmic reticulum (ER) stress (GRP78 increase) and the subcellular
distribution of the cytochrome C, as well as the overexpression of the pro-apoptotic protein BAX.
Immunocytochemical analysis as well as quantitative protein evaluation by western blotting revealed
that CBD partially counteracted the depletion of the growth associated protein 43 (GAP43) and of the
neuronal specific class III β-tubulin (β3 tubulin) induced by Cd treatment. These data showed that
Cd-induced neuronal injury was ameliorated by CBD treatment and it was concluded that CBD may
represent a potential option to protect neuronal cells from the detrimental effects of Cd toxicity.
Keywords: cadmium; cannabidiol; ER stress; ROS; SH-SY5Y; neurotoxicity
1. Introduction
Cadmium (Cd) is a transition heavy metal, chemically similar to zinc and mercury, the two
other metals in group 12, whose preferential oxidation state is +2. As an important component of
industrial processes such as metal plating, production of nickel-cadmium batteries, pigments, plastics,
and other synthetics, Cd has been seen as an occupational hazard [1]. On the other hand, tobacco
smoking, air pollution, and consumption of Cd-contaminated drinking water are the major sources
of non-occupational Cd exposure [2,3]. If the primary route of exposure in industrial settings is
inhalation of Cd-containing fumes, food and water are generally the largest sources of Cd exposure in a
nonsmoker population [4]. Epidemiological and experimental studies have linked the occupational Cd
exposure with lung cancer and other cancers such as the prostate, renal, liver, hematopoietic system,
urinary bladder, pancreatic, testis, and stomach cancers [5–7].
Exposure to Cd also severely affects the function of the nervous system [8–11], with symptoms
including headache and vertigo, olfactory and motor dysfunction, peripheral neuropathy, decreased
equilibrium and ability to concentrate, and learning disabilities [12–15]. Although studies on the
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central nervous system (CNS) Cd distribution demonstrated that this metal could not easily get into
the brain due to the presence of the blood brain barrier (BBB) [16,17], a Cd-induced BBB dysfunction
and permeability increase has been demonstrated in in vivo models [18]. Also, authors reported
the presence of BBB impairment in several neurodegenerative diseases, such as Alzheimer’s disease
(AD) and Parkinson’s disease (PD) [19,20]. Cd was shown to adversely influence the functions of
cholinergic and catecholaminergic systems [21], as well as the balance between excitation–inhibition
in synaptic neurotransmission [22]. Also, it has been proposed that chronic exposure to Cd can be
associated with an increased risk of developing PD [23]. Parkinson’s disease is a neurodegenerative
condition characterized by loss of dopaminergic neurons in the substantia nigra pars compacta with
resulting neurochemical imbalance throughout the basal ganglia [24]. Interestingly, this heavy
metal shows similar mechanisms of toxicity with other pollutants: they accumulate in the substantia
nigra and generate oxidative stress by increasing the production of reactive oxygen species (ROS)
and/or deregulating the antioxidant enzymes. This, in turn, produces the activation of the glia
inducing neuroinflammation, which increases the generation of further oxidative stress, leading to a
self-perpetuating cycle [25,26].
Although the mechanisms of Cd toxicity are poorly understood, the neurotoxicity of Cd is
attributable to the generation of ROS. Oxidative stress is generally defined as an imbalance that favors
the production of ROS and reactive nitrogen species (RNS) [27–29]. The major consequence induced
by Cd through oxidative stress is a ROS-mediated attack of double bonds in membrane lipids that
results in increased lipid peroxidation (LPO) as well as interference with the endogenous antioxidant
defenses in several organs and systems [27,30–33]. Indeed, Cd is known to induce a mitochondrial
membrane potential decrease and the consequent release of cytochrome C, eventually leading to the
activation of caspase-3 [34]. Furthermore, it has been demonstrated that Cd induces ER stress [21,35].
Previous in vitro and in vivo studies showed that Cd neurotoxicity was significantly attenuated
by antioxidants, anti-inflammatory, and metal-chelating agents [21,36–39]. Cannabis sativa has been
used for medicinal/recreational purposes for many years [40]. The two major components are
∆9-tetrahydrocannabinol (∆9-THC), the main psychoactive ingredient, and cannabidiol (CBD), the major
non-psychoactive component [41–43].
The adverse effects of cannabis are attributed to ∆9-THC [44], whereas CBD exhibits a variety of
therapeutic properties: anti-inflammatory, antidepressant, anxiolytic, immunomodulatory, antioxidant,
and neuroprotective effects [45–52].
CBD has been shown to reverse the increased excitotoxicity, inflammation, and oxidative stress in
ischemic brain damage and to protect PC12 and SH-SY5Y cells from tert-butyl-hydroperoxide-induced
oxidative stress [53]. Also, recent studies demonstrated that CBD was able to reverse the reductions in
synaptophysin levels and increases in caspase-3 levels induced by iron [54].
For this purpose, SH-SY5Y cell line presents many advantages including that can be differentiated
using retinoic acid (RA). Recently, Korecka and colleagues [55] have characterized the molecular
phenotype of RA-differentiated SH-SY5Y cells and concluded that these cells exhibit a dopaminergic
phenotype. The use of differentiated SH-SY5Y cells is well established as a cell culture model of PD [56].
In the present study, we provide evidence that CBD offers protection to neuronal cells against
Cd-induced oxidative stress by decreasing ROS production. Finally, we demonstrate the protective
effects of CBD against Cd-induced ER stress, pro-apoptotic BAX upregulation, cytochrome C release,
and the modifications in the expression levels and in the cellular distribution of the growth associated
protein 43 (GAP43) and of the neuronal specific class III β-tubulin (β3 tubulin), two proteins involved
in the neuronal sprouting.
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2. Materials and Methods
2.1. Cell Line
Human neuroblastoma SH-SY5Y cell line, was purchased by Istituto Zooprofilattico Sperimentale
della Lombardia e dell’Emilia-Romagna (Brescia, Italy). Cells were routinely cultured in DMEM
High Glucose/Ham’s F12 Mixture Medium (1:1 ratio), adding 10% fetal bovine serum (FBS), 2 mM
L-Glutamine (EuroClone S.p.a., Milano, Italy) and maintained at 37 ◦C, 5% CO2 in humidified
atmosphere. The growth medium was changed every 2–3 days.
In all the experiments pointed in this paper, SH-SY5Y cells were differentiated with 10 µM
all-trans retinoic acid (RA) (Sigma Aldrich, Milano, Italy) for 48 h in their appropriate medium (DMEM
High Glucose/Ham’s F12 Mixture Medium (1:1), 2 mM L-Glutamine) supplemented with 1% FBS,
as previously reported [21]. The 48 h differentiation was established because a prolonged SH-SY5Y
RA treatment induces cells to release cytochrome C from mitochondria to cytoplasm [57,58]. Briefly,
the cells were seeded in each support for 24 h in their complete growth medium. The next day, cells
were starved in 1% FBS medium for 48 h and differentiated by adding RA 10 µM. After two days of
differentiation, the cells were starved in 0% FBS medium for 24 h and then stimulated at different times
in starved medium (0% FBS) as reported below.
2.2. Treatment
In order to reproduce in vitro conditions that could mimic a chronic human Cd intoxication, we
decide to use a concentration of 10 µM of cadmium chloride (CdCl2) (Sigma Aldrich, Milano, Italy)
and a time of exposure of 24 h, as previously reported [21,59].
With the aim to figure out the neuro-protective effects of CBD, the concentration of 1 µM was chosen
on the basis of previously reported data [60] and performing dose response curves (data not shown).
Furthermore, since CBD has been evaluated in literature for its antioxidant effects [46,61],
we compared the CBD actions with αTocopheryl acetate (αToco) at 10 µM [62].
All treatments were performed in starvation medium because Cd effects could be impaired by
the presence of essential elements (such as zinc and calcium) in FBS. The timeline with the entire
experimental procedures was the following:
CdCl2 10 µM was placed in a starvation medium for 24 h. For pre-treatment experiments, CBD
1 µM or αToco 10 µM were added into the starvation medium for 24 h. The following day, the medium
was replaced with CdCl2 10 µM in the starvation medium for another 24 h.
2.3. MTT Assay
Cell viability was evaluated by the reduction of 3-(4,5-di-methyl-thiozol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) as an index of mitochondrial functional activity. Briefly, SH-SY5Y cells were seeded
into 96 well plates at a density of 20,000 cells/well in complete growth medium for one day and RA
differentiated. After differentiation, cells were treated with or without CdCl2 after the pre-treatment
with CBD or αToco. After removing the medium with different stimuli, 1 mg/ml MTT was added into
each well and incubated for at least 20 min at 37 ◦C. Following this, the chromogenic solution was
removed and replaced with 50 µL of dimethyl sulfoxide (DMSO) to dissolve the formazan crystals,
and the absorbance was measured at 595 nm wavelength by a Multiscan FC photometer (ThermoFisher
Scientific, Milano, Italy). Three independent experiments were performed, and each experiment was
performed in quintuplicate.
2.4. ROS Evaluation
To assay the intracellular ROS production, 7×104 SH-SY5Y cells were seeded on square
(22 × 22 mm) glass cover slip slides and lodged in 6 multi-well plates. After RA differentiation
and CdCl2, CBD, αToco appropriate stimulation, cells were loaded with 10 µM 2,7-dichlorodihydro-
fluorescein diacetate for 10 min (CM-H2DCFDA, ThermoFisher Scientific, Milano, Italy), as previously
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described [63]. Cell fluorescence was captured by the motorized Leica DM6000B microscope equipped
with a DFC350FX (Leica, Mannheim, Germany). The microscope was set at optimal acquisition
conditions, and settings were kept constant for each analysis. Five microscopic fields for each
experimental point were analyzed.
Fluorescence intensity was processed by ImageJ analysis software (ImageJ, National Institute of
Health, Bethesda, MD, USA, https://imagej.nih.gov/ij/, version 1.52 q) and the results were expressed
as a percentage of control.
Each experiment was performed in triplicate, and three different experiments were set up.
Furthermore, a positive control was performed treating SH-SY5Y with H2O2 (Sigma Aldrich, Milano,
Italy) 200 µM for 24 h (supplementary Figure S1).
2.5. Western Blotting Analysis
SH-SY5Y cells were plated in Petri dishes in complete growth medium at the density of 107 cells/well
and treated as described above. After each treatment, the medium was removed and two washes
with PBS (phosphate buffered saline) were performed. The cells were scraped from the surface of
the dishes and the cell suspensions were centrifuged at 1000 rpm for 10 min at room temperature
(RT). After removing the supernatant, the pellets were treated with lysis buffer (TRIS 50 mM, pH 7;
NaCl 150 mM; 1% TRITON X-100; EDTA 1.5 mM; 0.25% SDS) containing a protease inhibitors cocktail
(Sigma Aldrich, Milano, Italy) for 30 min at 4 ◦C. The homogenates were centrifuged at 4 ◦C for
10 min at 12,000 rpm and the obtained supernatants were used to evaluate the protein concentration by
Bradford’s method. Equal amounts of proteins (30 µg) were analyzed on a 12–14% polyacrylamide gel,
subjected to protein molecular weight, and then transferred onto nitrocellulose membrane (Porablot
NPC, MACHEREY-NAGEL, Milano, Italy). After 1 h blocking with 3% bovine serum albumin (BSA)
in Tris-buffered saline containing 0.1% Tween 20 (T-TBS) at RT, the blot was incubated overnight
at 4 ◦C with the following primary antibodies: 1:500 mouse monoclonal anti-GAP43 (B-5), 1:10,000
mouse monoclonal anti-β-actin (C4), 1:300 rabbit polyclonal anti-BAX (P-19), 1:500 rabbit polyclonal
anti-cytochrome C (H-104) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 1:500 rabbit polyclonal
anti-GRP78 antibody (ThermoFischer Scientific, Milano, Italy), 1:10,000 rabbit polyclonal anti-GAPDH
(Cell Signaling, Boston, MA, USA), and then with 1:5000 goat anti-mouse (for GAP43 and β-actin) and
goat anti-rabbit (for BAX, cytochrome C, GRP78 and GAPDH) HRP secondary antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 h at RT. The protein amounts were detected with the
Amersham ECL Plus Western Blotting Detection Reagent (GE Healthcare, Milano, Italy). Protein
expression levels were then quantified by ImageJ analysis software and expressed as a percentage
of control.
Each experiment was performed in triplicate, and three different experiments were performed.
2.6. Immunofluorescent Staining
SH-SY5Y cells were seeded on square (22 × 22 mm) glass cover slip slides lodged in 6 multi-well
plates at the density of 7 × 104 cells/well. As described above, RA differentiated SH-SY5Y were treated
with CdCl2 with or without CBD or αToco. At the end of each treatment, the starvation medium
containing stimuli was removed and two washes with cold PBS were performed. The cells were then
fixed with 1 mL of 4% paraformaldehyde for 10 min at RT. After three more washes with cold PBS
(5 min for each wash), the cells were permeabilized with 0.1% TRITON X-100 in PBS for 10 min at
RT. Cells were then washed three times with PBS and incubated for at least 15 min in a blocking
solution (1% BSA in PBS) at RT. Then, each cover slip was incubated overnight at 4 ◦C with the
following primary antibodies at 1:200 dilution: mouse monoclonal anti-β3 tubulin (TU-20), mouse
monoclonal anti-GAP43 (B-5), rabbit polyclonal anti-cytochrome C (H-104) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The day after, cells were washed three times with PBS and each cover slip
was incubated with 1:200 dilution Alexa Fluor 568 goat anti-mouse (for β3 tubulin and GAP43) or
488 goat anti-rabbit (for cytochrome C) immunoglobulin G (IgG) secondary antibodies (ThermoFisher
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Scientific, Milano, Italy) for 1 h at RT. After secondary antibody incubation, two washes were performed
with PBS and DAPI (4′,6-dia-midin-2-fenilindolo; 1:2000 dilution; ThermoFisher Scientific, Milano,
Italy) was added for 5 min at RT to each cover slip. Eventually, after two more washes in cold PBS
and one more in distilled water, cover slip glasses were mounted by Fluoromount anti-fade solution
(ThermoFischer Scientific, Milano, Italy) on cover slides. Digitalized images were collected at 200×
or 400× total magnification by a motorized Leica DM6000B microscope equipped with a DFC350FX.
Five microscopic fields for each experimental point were analyzed.
All data were reported after normalization for the total number of cells per field. Each experiment
was performed in triplicate, and three different experiments were set up.
2.7. Statistical Analysis
Statistical analysis was performed by Two-way Analysis of Variance (ANOVA) followed by the
Tukey test. All assessments were made by researchers blinded to treatments. Data were analyzed using
“Origin 9” software (OriginLab, Northampton, MA, USA). Differences were considered significant at
p < 0.05.
3. Results
3.1. Cell Viability
To evaluate RA differentiated SH-SY5Y cell viability after treatments with CdCl2 10 µM with
or without CBD 1 µM and αToco 10 µM, an MTT assay was performed. As shown in Figure 1, cell
viability was significantly (* p < 0.05) decreased after 24 h treatment with CdCl2. In contrast, both CBD
and αToco were able to prevent the decrease of cell viability when used as pre-treatment for 24 h before
adding CdCl2.
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Figure 1. Cell viability on retinoic acid (RA) differentiated SH-SY5Y. An 3-(4,5-di-methyl- thiozol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was used to evaluate CdCl2 10 μM effects after 
cannabidiol (CBD) 1 μM or αToco 10 μM pre-treatment. As expected, a Cd-dependent significant 
reduction of cell viability was observed (dark column). Dissimilarly, both CBD (dotted column) and 
αToco (wavy column) clearly prevented Cd-induced neurotoxicity. Results are expressed as mean 
value ± S.E.M. Control, untreated cells, were taken as 100%. Each experimental point was performed 
in quintuplicate, from three independent set of experiments. * p < 0.05 vs Ctrl; # p < 0.05 vs. Cd. 
3.2. SH-SY5Y ROS Production 
In order to evaluate the effects of CBD and αToco on Cd-induced ROS generation leading to 
oxidative stress, RA differentiated SH- SY5Y cells were treated with 10 μM CdCl2 for 24 h after the 
pre-treatment with or without CBD 1μM and αToco 10 μM. The fluorescent images (Figure 2A), 
clearly showed that CdCl2 increased the amounts of ROS, confirming the oxidative role of Cd leading 
to neuronal toxicity, as previously reported [64]. On the other hand, both CBD and αToco seemed to 
Figure 1. Cell viability on retinoic acid (RA) differentiated SH-SY5Y. An 3-(4,5-di-methyl-thiozol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was used to evaluate CdCl2 10 µM effects after cannabidiol
(CBD) 1 µM or αToco 10 µM pre-treatment. As expected, a Cd-dependent significant reduction of
cell viability was observed (dark column). Dissimilarly, both CBD (dotted column) and αToco (wavy
column) clearly prevented Cd-induced neurotoxicity. Results are expressed as mean value ± S.E.M.
Control, untreated cells, were taken as 100%. Each experimental point was performed in quintuplicate,
from three independent set of experiments. * p < 0.05 vs. Ctrl; # p < 0.05 vs. Cd.
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3.2. SH-SY5Y ROS Production
In order to evaluate the effects of CBD and αToco on Cd-induced ROS generation leading to
oxidative stress, RA differentiated SH-SY5Y cells were treated with 10 µM CdCl2 for 24 h after the
pre-treatment with or without CBD 1 µM and αToco 10 µM. The fluorescent images (Figure 2A),
clearly showed that CdCl2 increased the amounts of ROS, confirming the oxidative role of Cd leading
to neuronal toxicity, as previously reported [64]. On the other hand, both CBD and αToco seemed
to be protective against Cd-induced oxidative stress. The semi-quantitative analysis of ROS levels
(Figure 2B), better highlighted the Cd-induced ROS increment, as well as the effectiveness of CBD or
αToco in RA differentiated SH-SY5Y.
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Figure 2. Immunofluorescence staining and ROS production quantification. ROS expression was quantified by
the 2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) probe. (A) Representative fluorescent
images of intracellular ROS levels after CdCl2 10 µM treatment, with or without CBD or αToco
pre-treatment. (B) Fluorescence semi-quantitative analysis highlighting the role of Cd (dark column)
in increasing ROS production and the role of CBD (dotte column) or αToco (wavy column) in
preventing ROS formati n. The intracellular ROS-derived fluorescence i xpres ed as the percentage
of fluorescence compar d to control, untrea ed cells, taken as 100%. Results ar express d as mean
± S.E.M. Each experiment point was performed in triplicate, from thr e different set o experiments.
Fiv different microscopic fields fo each experimental point w e analyzed. Total magnification: 400×.
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3.3. Cd-Induced ER Stress and Apoptotic Cascade Signaling
To bett r figure out the ER stress induced by the f , e evaluated th expression of
GRP78, a HSP70 molecular chaperone well known to be evoked during ER stress [ . ,B,
the his ogram cle rly show CdCl2 (dark columns) treatment is able to over-express GRP78. This
deleterious effect was prevented by the pre-treatment with CBD (Figure 3A, dark dotted column) and
αToco (Figure 3B, wavy dark column) as well.
Moreover, since Cd is well known to activate the apoptotic pathway [34], the expression levels of
the pro-apoptotic protein BAX (Figure 4A,B), were investigated during CBD and αToco pre-treatment
in RA differentiated SH-SY5Y. Our results undoubtedly showed an increment in BAX expression
level after 24 h CdCl2 (dark columns) treatment, while both CBD and αToco pre-treatment showed a
protective effect, preserving low BAX levels superimposable to control amounts.
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Figure 3. Western blotting analysis on ER stress. Western blotting analysis showed that CdCl2 10 µM
significantly increased SH-SY5Y ER stress, by the up-regulation of GRP78 (dark columns). On the
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treated with CBD or αToco, the cytochrome C remained poorly labeled close to the nuclei as seen in 
control, untreated cells. This last result was highlighted by western blotting analysis (Figure 5B). The 
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Figure 4. Western blotting analysis on pro-apoptotic protein. Consistent with Cd-induced SH-SY5Y ER
stress, the histograms clearly showed a significant increase in BAX protein expression after 24 h CdCl2
treatment (dark columns). The pre-treatment with CBD 1 µM (A—dark dotted column) and αToco
10 µM (B—dark wavy column), were able to sig ificantly retain low level of the ro-apoptotic BAX
protein a ted by western blotting analysis. Results are expre sed as mean ± S.E.M. Control,
untreate ere taken as 100%. T e housekeeping β-actin protein was used as an inte nal control
for protei or alization. Each experiment point was performed in triplicate, from three different set
of experiments. * p < 0.05 vs. Ctrl; # p < 0.05 vs. Cd.
These results collimate with the mitochondrial spillage of cytochrome C in the cytoplasm. Indeed,
as displayed in Figure 5A, the immunofluorescent staining of cytochrome C revealed an increase during
24 h CdCl2 treatment. Nevertheless, when RA differentiated SH-SY5Y were pre-treated with CBD or
αToco, the cytochrome C remained poorly labeled close to the nuclei as seen in control, untreated cells.
This last result was highlighted by western blotting analysis (Figure 5B). The densitometric analysis
of cytoplasm protein expression levels revealed a high amou t of cytochrome C during CdCl2 (dark
columns) tr atment, which was retain d at a lower level when RA differentiated SH-SY5Y were in the
presence of CBD (dotted dark column) or αToco (wavy dark column).
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3.4. Neuronal Sprouting
These detrimental effects induced by Cd may affect neuronal sprouting. For this reason, we
evaluated the expression of GAP43 in RA differentiated SH-SY5Y cells during CdCl2 treatment in the
presence or absence of CBD and αToco. As shown in Figure 6A, Cd-treated cells express low levels of
perinuclear GAP43, compared to control, untreated cells. On the other hand, when our cellular model
was pre-treated with CBD or αToco, the immunofluorescent staining revealed a higher presence of
GAP43 that was maintained at control amounts. Furthermore, western blotting analysis (Figure 6B),
completely correlate with immunofluorescent staining performed. Indeed, since CdCl2 (dark columns)
treatment decrease GAP43 expression, CBD (dotted dark column) and αToco (wavy dark column)
pre-treatment were able to prevent the GAP43 decrease, retaining levels that are superimposable to
control amounts. Taken together, these results encouraged us to better investigate the protective role of
CBD in neuronal branching, looking at β3 tubulin.
The immunofluorescent staining of β3 tubulin (Figure 7A) corroborate and support the GAP43
expression. Indeed, the cytoplasmic elongation clearly decreased when cells were treated with CdCl2
10 µM for 24 h, and β3 tubulin appeared abundant in the cell soma, alongside the nuclei. Interestingly,
when RA differentiated SH-SY5Y were pre-treated with CBD or αToco, the neuronal sprouting was
maintained, hypothesizing the protective role of CBD against the Cd neuro-toxic effects and neurite
loss. To better underline the positive role of CBD in counteracting Cd neurite loss, the occurrence of
neuronal sprouting was quantified by Fiji software (ImageJ, Bethesda, MD, USA), and then normalized
on nuclei counting (Figure 7B).
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Figure 7. β3 tubulin expression on SH-SY5Y. (A) the immunofluorescence staining revealed a very strong
decrease of cytoplasmic elongations in CdCl2-treated cells. This deleterious event was prevented by the
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Scale bar: 50 µm.
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4. Discussion
In recent years, there has been an increasing ecological and global public health concern associated
with environmental contamination by heavy metals. As a result of an exponential increase of their
use in several industrial, agricultural, domestic, and technological applications, human exposure to
these metals has risen dramatically [66]. Although heavy metals are naturally occurring elements,
most environmental contamination and human exposure result from anthropogenic activities such as
mining and smelting operations, industrial production and use, and domestic and agricultural use of
metals and metal-containing compounds [67–70].
Cadmium is a heavy metal of considerable environmental and occupational concern [71]. Human
exposure to Cd is possible through a number of several sources including employment in primary
metal industries, emissions from industrial activities, including mining, smelting, and manufacturing
of batteries, pigments, stabilizers, and alloys [72].
Agricultural and industrial activities have led to the entry of Cd into the soil and subsequently
into ground and drinking water. Due to the highly soluble nature of Cd compounds compared to other
metals, it is readily taken up by plants, resulting in storage in crops for food and feed production.
This high soil-to-plant transfer rate makes the diet, in general, the primary source of Cd exposure in
non-occupationally exposed populations [4].
Occupational exposure to Cd takes place in industrial factories, where it is frequently used [73],
such as from zinc (Zn) smelters, battery manufacturing and metal recovering factories, Cd refining
companies, paint, and pigment production units, as well as via other anthropogenic factors like waste
incineration and fossil fuel combustion [30].
Once absorbed, Cd is reported to accumulate in several tissues, which might cause harmful effects
including renal dysfunction, pulmonary edema, several different organ cancers, cardiovascular disease,
airway inflammation, diabetes, and neurological diseases [74]. Cd has been regarded as a possible
etiological factor for human neurodegenerative diseases, such as PD and AD [23]. Indeed, over the last
several years many studies have extensively demonstrated that exposure to different environmental
factors could be a significant risk factor for the development of PD [25,75]. Even if the etiology of this
disease is still unclear, the role of the environment as a putative risk factor has gained importance.
Moreover, neurotoxic metals, including Cd, have been involved in PD [23].
Normal blood plasma Cd concentrations in adults without excessive exposure are generally
8–30 nM [76,77], other authors consider as normal the range 1.8–50 nM [78]; recently the World Health
Organization (WHO) [71] reported that an acceptable blood level of Cd is in the range of 2–10 nM.
Concentrations above 0.045 µM are warrant careful investigation [79]. About the definition of a toxic
blood levels there are some discrepancies; in 1980, Kaye reported that the approximate lethal blood
level is 4.5 µM [77]. A recent paper regarding the blood Cd levels of Nigerian subjects exposed to
this metal were showed that the mean blood value was 4 µM without declared toxic effects but only
“increased health risk” [80]. Acute poisoning with marked lethargy and fever was reported with blood
Cd concentration 0.25 µM [78].
In vitro data are quite different, where 0.5 µM is considered an ultra-low Cd concentration able to
attenuate angiogenesis in both the wound healing assay and the chick chorioallantoic membrane (CAM)
assay. In addition, the same concentration of Cd reduces bradykinin (BK), a powerful angiogenic agent,
and mediate both tube formation in 3D matrigel matrix and ex vivo angiogenesis in CAM models,
suggesting a protective role of Cd against tumor angiogenesis [81].
On the basis of this evidence, concentrations ranging from 1 to 10 µM (one of those used in
the present work) can be considered relevant for mimicking Cd-mediated damage of tissues or
body compartments [59]. Moreover, based on previously reported data [82–84] we adopted the best
experimental conditions that could better reflect an in vivo situation, thereby mimicking chronic
exposure conditions. For this reason, we chose the concentration of 10 µM that was low cytolytic but,
at the same time, enabled us to study the Cd effects at the cellular level.
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CBD is the second major component of the Cannabis sativa and, with respect to the first component
∆9-THC, is not associated with psychoactivity. CBD possesses numerous per se pharmacological
effects, reducing the collateral effects of ∆9-THC, thus ameliorating its safety profile [85,86]. Moreover,
it displays lower CB1 and CB2 receptor affinity with respect to ∆9-THC. CB1 receptors are expressed
most densely in the CNS and are largely responsible for mediating the effects of cannabinoid binding
in the brain [87–89]. CB2 receptors are preferentially expressed in the immune and gastrointestinal
systems, even if a very low expression has been identified in some neurons within the CNS
(e.g., the brainstem) [90,91]. CBD also interacts with several other recently discovered CB receptors,
and it is an agonist for the 5-HT1A receptor [92,93], which may explain some of the antipsychotic
and anxiolytic effects of CBD [94]. Dopamine receptors have been identified as other targets of CBD,
in particular it is a partial agonist of the D2 receptor (D2R) [95]. Also, the highly lipophilic nature of
cannabinoids allows CBD to enter freely the cells [96].
The mechanisms by which CBD exerts its effect are not precisely known, but it is clear that the
pharmacological actions of CBD follow from many different mechanisms [43,97].
Many studies with CBD used in vivo models [53] but the evaluation of the effects of CBD on
neurobehavioral and neuropathological processes is expensive, time consuming, and is not suitable
to predict human neurotoxicity. Cellular models are instrumental for in vitro or ex vivo studies to
analyze the cellular pathways that govern physiological or pathological processes, or to evaluate the
cell toxicity or protection induced by different compounds, including potential drugs.
In the present study, we have investigated the protective effect of treatment with CBD on
RA-differentiated SH-SY5Y neuroblastoma cells that show a dopaminergic-like phenotype. These cells
not only provide a human cell culture model of PD, but also possess important characteristics that
make them particularly useful for analyzing the effects of CBD against the neurotoxicity induced by
Cd. Indeed, it has been already demonstrated that neuronal SH-SY5Y cells selectively express the CB1
receptor [98]. Moreover, RA-dependent neuronal differentiation was associated with a strong induction
of CB1R [99] and a strong increase in dopamine receptor subtypes (D2R and D3R), and dopamine
transporter (DAT) expression [100–102].
Moreover, the effects of CBD were then compared with (αToco), a known antioxidant.
Our results, consistent with the antioxidant properties attributed to this compound in different
experimental models [103], demonstrate that the exposure of RA-differentiated neuroblastoma cells to
Cd induced intracellular ROS production at 24 h post treatment. By comparison, CBD pre-treatment
reduced the Cd-dependent ROS increment, acting as ROS scavenger.
Moreover, Cd induced the release of cytochrome C from mitochondria and the upregulation of
the pro-apoptotic protein BAX expression levels. These effects, already proven to be a consequence of
the ROS formation [104–107], are partially prevented by the action of CBD.
Given the notion that oxidative stress triggered ER stress [108], we measured the expression
levels of GRP78, a known unfolded protein response (UPR)-related chaperone [65,109–111] in the
presence and in the absence of CBD. We observed that after 24 h of exposure to Cd the presence of
CBD significantly prevented the Cd-dependent GRP78 upregulation. This result is interesting when
compared with αToco that slightly counteracts Cd-induced ER stress. Indeed, CBD was seen to exploit
this effect both as an anti-oxidant and as an ER stress attenuator [112,113], on the other hand, αToco
mainly acts as an anti-oxidant molecule.
Finally, as previously demonstrated [21], Cd is able to induce a downregulation of GAP43
expression and an altered distribution of β3 tubulin, two proteins involved in neurite outgrowth
and neurogenesis and axon guidance and maintenance, respectively. This effect is prevented by the
CBD treatment.
In summary, the findings presented here indicate that CBD exerts protective effects in
RA-differentiated SH-SY5Y cells under Cd treatment, a condition of oxidative and ER stress. In conditions
of oxidative stress, the protective effect of CBD was mediated by a decrease in ROS production; also, CBD
combated apoptosis by decreasing cytochrome C mitochondrial extrusion and downregulating BAX,
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and avoids ER stress through the modulation of GRP78 protein. Finally, CBD prevents the Cd-dependent
inhibition of neuronal sprouting, as determined by the evaluation of GAP43 expression levels and
β3 tubulin intracellular distribution. We propose that CBD, a Cannabis sativa derivative that lacks
psychoactive properties, is a good candidate provide protection from Cd-induced neurotoxic threats.
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Figure S1: Immunofluorescence staining of ROS positive control.
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